U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sharma P, Scotland G, Cruickshank M, et al. The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2015 Jun. (Health Technology Assessment, No. 19.48.)

Cover of The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation.

Show details

References

1.
National Insititute for Health and Care Excellence. Anticoagulation Therapy Service Commissioning Guide. 2010. URL: www​.nice.org.uk/usingguidance​/commissioningguides​/anticoagulationtherapyservice​/anticoagulationtherapyservice.jsp (accessed October 2013).
2.
Cayley J. Self-monitoring and self-management of anticoagulation therapy. Am Fam Physician 2011;84:266–8. [PubMed: 21842772]
3.
Rose PE. Audit of anticoagulant therapy. J Clin Pathol 1996;49:5–9. 10.1136/jcp.49.1.5. [PMC free article: PMC1023148] [PubMed: 8666686] [CrossRef]
4.
Ahmad Y, Lip GY, Lane DA. Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. Can J Cardiol 2013;29(Suppl. 7):S4–13. 10.1016/j.cjca.2013.03.009. [PubMed: 23790597] [CrossRef]
5.
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–5. 10.1001/jama.285.18.2370. [PubMed: 11343485] [CrossRef]
6.
Tamayo AE, Vergara-Mitxeltorena I, Uranga Saez del BE, Ostiza-Irigoyen A, Garcia-Carro A, Lopez-Fernandez I, et al. Oral anticoagulation and self-management: analysis of the factors that determine the feasibility of using self-testing and self-management in primary care. BMC Cardiovas Disord 2013;13:59. 10.1186/1471-2261-13-59. [PMC free article: PMC3765739] [PubMed: 23968316] [CrossRef]
7.
European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–429. 10.1093/eurheartj/ehq278. [PubMed: 20802247] [CrossRef]
8.
Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med 2013;274:461–8. 10.1111/joim.12114. [PubMed: 23879838] [CrossRef]
9.
DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006;92:1064–70. 10.1136/hrt.2005.069492. [PMC free article: PMC1861124] [PubMed: 16387813] [CrossRef]
10.
Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N–9N. 10.1016/S0002-9149(98)00583-9. [PubMed: 9809895] [CrossRef]
11.
Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998;352:1167–71. 10.1016/S0140-6736(98)01401-9. [PubMed: 9777832] [CrossRef]
12.
Dunning J, Nagendran M, Alfieri OR, Elia S, Kappetein AP, Lockowandt U, et al. Guideline for the surgical treatment of atrial fibrillation. Eur J Cardiothorac Surg 2013;44:777–91. 10.1093/ejcts/ezt413. [PubMed: 23956274] [CrossRef]
13.
British Heart Foundation. Heart Valve Disease. 2013. URL: www​.bhf.org.uk/heart-health​/conditions/heart-valve-disease​.aspx (accessed October 2013).
14.
Patient.co.uk. Aortic Stenosis. 2013. URL: www​.patient.co.uk/health/aortic-stenosis (accessed October 2013).
15.
NHS Health and Social Care Information Centre. UK Heart Valve Registry. 2010. URL: http://docdat​.ic.nhs​.uk/DatabaseList.aspx (accessed October 2013).
16.
NHS Choices. Aortic Valve Replacement. 2013. URL: www​.nhs.uk/conditions​/Aorticvalvereplacement​/Pages/Whatisitpage.aspx (accessed October 2013).
17.
Jones S, Monagle P, Manias E, Bruce AA, Newall F. Quality of life assessment in children commencing home INR self-testing. Thromb Res 2013;132:37–43. 10.1016/j.thromres.2013.05.011. [PubMed: 23726963] [CrossRef]
18.
Pollack CV Jr. Managing bleeding in anticoagulated patients in the emergency care setting. J Emerg Med 2013;45:467–77. 10.1016/j.jemermed.2013.03.016. [PubMed: 23786779] [CrossRef]
19.
Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006;8:651–745. [PubMed: 16987906]
20.
You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl.):e531S–75S. [PMC free article: PMC3278056] [PubMed: 22315271]
21.
Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007;11(38). 10.3310/hta11380. [PubMed: 17903392] [CrossRef]
22.
British Heart Foundation. Atrial Fibrillation. 2013. URL: www​.bhf.org.uk/heart-health​/conditions/atrial-fibrillation​.aspx (accessed October 2013).
23.
NHS Improvement. Atrial fibrillation. NHS Stroke Improvement Programme; 2013. URL: www​.improvement.nhs.uk​/heart/HeartImprovementHome​/AtrialFibrillation​/tabid/128/Default.aspx (accessed October 2013).
24.
National Insititute for Health and Care Excellence. Atrial Fibrillation. Clinical guideline CG36. London: National Insititute for Health and Care Excellence; 2006. URL: http://guidance​.nice​.org.uk/CG36/NICEGuidance/pdf/English (accessed October 2013).
25.
Health Improvement Scotland. SIGN 129 Antithrombotics: Indications and Management. 2012. URL: www​.sign.ac.uk/pdf/SIGN129.pdf (accessed October 2013).
26.
Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J 2007;28:230–68. [PubMed: 17259184]
27.
Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Systematic Reviews in Health Care. University of York: Centre for Reviews and Dissemination; 2009. URL: www​.york.ac.uk/inst/crd​/SysRev/!SSL!/WebHelp/SysRev3.htm (accessed October 2013).
28.
Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. URL: www​.cochrane-handbook.org/ (accessed October 2013).
29.
National Institute for Health and Care Excellence. NICE Diagnostic Assessment Programme Manual. 2011. URL: www​.nice.org.uk/media​/A0B/97/DAPManualFINAL.pdf (accessed October 2013). [PubMed: 27466648]
30.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12. 10.1016/j.jclinepi.2009.06.005. [PubMed: 19631508] [CrossRef]
31.
Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010;4:CD003839. 10.1002/14651858.CD003839.pub2. [PubMed: 20393937] [CrossRef]
32.
Brown A, Wells P, Jaffey J, McGahan L, Poon MC, Cimon K, et al. Point-of-Care Monitoring Devices for Long-Term Oral Anticoagulation Therapy: Clinical and Cost-Effectiveness. Technology report no. 72. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2007. URL: www​.cadth.ca/media/pdf​/H0299_anticoagulation-therapy_tr_e​.pdf (accessed October 2013).
33.
Gailly J, Gerkens S, van den Bruel A, Devriese S, Obyn C. Use of Point-of-Care Devices in Patients with Oral Anticoagulation: A Health Technology Assessment. KCE Report 117C. Brussels: Belgian Health Care Knowledge Centre; 2009. URL: https://kce​.fgov.be/publication​/report/use-of-point-of-care-devices-in-patients-with-oral-anticoagulation-a-health-techn (accessed October 2013).
34.
Christensen TD, Larsen TB, Jensen C, Maegaard M, Sorensen B. International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy. Thromb Haemostast 2009;101:563–9. [PubMed: 19277421]
35.
Christensen TD, Larsen TB. Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. J Thromb Haemostas 2012;10:251–60. 10.1111/j.1538-7836.2011.04568.x. [PubMed: 22118602] [CrossRef]
36.
Sobieraj-Teague M, Daniel D, Farrelly B, Coghlan D, Gallus A. Accuracy and clinical usefulness of the CoaguChek S and XS Point of Care devices when starting warfarin in a hospital outreach setting. Thromb Res 2009;123:909–13. 10.1016/j.thromres.2008.10.006. [PubMed: 19042011] [CrossRef]
37.
US Food and Drug Administration. CoaguChek® XS System (Patient Self-Testing): Substantial Equivalence Determination Decision Summary 510(k)062925. Silver Spring, MD: US Food and Drug Administration Agency; 2007. URL: www​.accessdata.fda.gov​/scripts/cdrh/cfdocs/cfpmn/pmn​.cfm?ID=22917 (accessed October 2013).
38.
US Food and Drug Administration. Alere INRatio®2 PT/INR Home Monitoring System: Substantial Equivalence Determination Decision Summary 510(k)110212. Silver Spring, MD: US Food and Drug Administration Agency; 2012. URL: www​.accessdata.fda.gov​/scripts/cdrh/cfdocs/cfpmn/pmn​.cfm?ID=36124 (accessed October 2013).
39.
US Food and Drug Administration. ProTime Microcoagulation System: Substantial Equivalence Determination Decision Summary 510(k)010599. Silver Spring, MD: US Food and Drug Administration Agency; 2001. URL: www​.accessdata.fda.gov​/scripts/cdrh/cfdocs/cfpmn/pmn​.cfm?ID=3783 (accessed October 2013).
40.
Medicines and Healthcare products Regulatory Agency. Patient Self-Testing Using the Roche Coaguchek S. MHRA report 04002. London: Medicines and Healthcare products Regulatory Agency; 2004. URL: http://nhscep​.useconnect​.co.uk/ShowDocument​.ashx?id=323&i=true (accessed October 2013).
41.
Canadian Agency for Drugs and Technologies in Health. Point-of-Care Testing: A Review of Systematic Reviews on Testing Accuracy and Cost-Effectiveness. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2012. URL: www​.cadth.ca/media/pdf​/htis/april-2012/RC0345​%20Point%20of%20Care​%20Testing%20Final.pdf (accessed October 2013).
42.
Ansell J, Jacobson A, Levy J, Voller H, Hasenkam JM, International Self-Monitoring Association for Oral Anticoagulation. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol 2005;99:37–45. 10.1016/j.ijcard.2003.11.008. [PubMed: 15721497] [CrossRef]
43.
Bauman ME, Black KL, Massicotte MP, Bauman ML, Kuhle S, Howlett-Clyne S, et al. Accuracy of the CoaguChek XS for point-of-care international normalized ratio (INR) measurement in children requiring warfarin. Thromb Haemostas 2008;99:1097–103. 10.1160/TH07-10-0634. [PubMed: 18521514] [CrossRef]
44.
Bereznicki LR, Jackson SL, Peterson GM, Jeffrey EC, Marsden KA, Jupe DM. Accuracy and clinical utility of the CoaguChek XS portable international normalised ratio monitor in a pilot study of warfarin home-monitoring. J Clin Pathol 2007;60:311–14. 10.1136/jcp.2006.037820. [PMC free article: PMC1860570] [PubMed: 16751303] [CrossRef]
45.
Gardiner C, Williams K, Mackie IJ, Machin SJ, Cohen H. Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. Br J Haematol 2005;128:242–7. 10.1111/j.1365-2141.2004.05300.x. [PubMed: 15638860] [CrossRef]
46.
Havrda DE, Hawk TL, Marvin CM. Accuracy and precision of the CoaguChek S versus laboratory INRs in a clinic. Ann Pharmacother 2002;36:769–75. 10.1345/aph.1A310. [PubMed: 11978150] [CrossRef]
47.
Hentrich DP, Fritschi J, Muller PR, Wuillemin WA. INR comparison between the CoaguChek S and a standard laboratory method among patients with self-management of oral anticoagulation. Thromb Res 2007;119:489–95. 10.1016/j.thromres.2006.04.003. [PubMed: 16765423] [CrossRef]
48.
Jackson SL, Bereznicki LR, Peterson GM, Marsden KA, Jupe DM, Vial JH, et al. Accuracy and clinical usefulness of the near-patient testing CoaguChek S international normalised ratio monitor in rural medical practice. Aust J Rural Health 2004;12:137–42. 10.1111/j.1440-1854.2004.00585.x. [PubMed: 15315540] [CrossRef]
49.
Kitchen S, Kitchen D, Jennings I, Woods T, Walker I. External quality assessment of CoaguChek point-of-care testing prothrombin time/international ratio monitors. Am J Clin Pathol 2008;129:825–6. [PubMed: 18481407]
50.
Moon JR, Jeong SI, Huh J, Lee HJ, Park PW, Kang IS. Accuracy of CoaguChek XS for point-of-care antithrombotic monitoring in children with heart disease. Ann Clin Lab Sci 2010;40:247–51. [PubMed: 20689136]
51.
Braun S, Watzke H, Hasenkam JM, Schwab M, Wolf T, Dovifat C, et al. Performance evaluation of the new CoaguChek XS system compared with the established CoaguChek system by patients experienced in INR-self management. Thromb Haemostas 2007;97:310–14. [PubMed: 17264962]
52.
Paioni P, Kroiss S, Kagi E, Bergstrasser E, Fasnacht M, Bauersfeld U, et al. Self-monitoring of oral anticoagulation therapy in children. Acta Haematol 2009;122:58–63. 10.1159/000243726. [PubMed: 19816011] [CrossRef]
53.
Williams VK, Griffiths AB. Acceptability of CoaguChek S and CoaguChek XS generated international normalised ratios against a laboratory standard in a paediatric setting. Pathology 2007;39:575–9. 10.1080/00313020701684797. [PubMed: 18027261] [CrossRef]
54.
Ryan F, O’Shea S, Ortel TL, Byrne S. The reliability of point-of-care (POC) prothrombin time testing: a comparison of CoaguChek XS(R) INR measurements with hospital laboratory monitoring. Blood 2007;110:abstract 973. [PubMed: 19032373]
55.
Bauman ME, Black K, Bauman ML, Bruce AA, Kuhle S, Bajzar L, et al. EMPoWarMENT: Edmonton pediatric warfarin self-management pilot study in children with primarily cardiac disease. Thromb Res 2010;126:e110–15. 10.1016/j.thromres.2010.05.024. [PubMed: 20584541] [CrossRef]
56.
Gardiner C, Williams K, Longair I, Mackie IJ, Machin SJ, Cohen H. A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing. Br J Haematol 2006;132:598–603. 10.1111/j.1365-2141.2005.05899.x. [PubMed: 16445833] [CrossRef]
57.
Hemkens LG, Hilden KM, Hartschen S, Kaiser T, Didjurgeit U, Hansen R, et al. A randomized trial comparing INR monitoring devices in patients with anticoagulation self-management: evaluation of a novel error-grid approach. J Thromb Thrombolysis 2008;26:22–30. 10.1007/s11239-007-0070-4. [PubMed: 17965836] [CrossRef]
58.
Rasmussen RS, Corell P, Madsen P, Overgaard K. Effects of computer-assisted oral anticoagulant therapy. Thrombosis J 2012;10:17. 10.1186/1477-9560-10-17. [PMC free article: PMC3502261] [PubMed: 22935243] [CrossRef]
59.
Horstkotte D, Piper C, Wiemer M, Schulte H.D. Improvement of prognosis by home prothrombin estimation In patients with life-long anticoagulant therapy. Eur Heart J 1996;17:230.
60.
Völler H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study). Zeitschrift für Kardiologie 2005;94:182–6. 10.1007/s00392-005-0199-0. [PubMed: 15747040] [CrossRef]
61.
Menéndez-Jándula JB, Souto JC, Oliver A, Montserrat I, Quintana M, Gich I, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 2005;142:1–10. 10.7326/0003-4819-142-1-200501040-00006. [PubMed: 15630104] [CrossRef]
62.
Ryan F, Byrne S, O’Shea S. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J Thromb Haemost 2009;7:1284–90. 10.1111/j.1538-7836.2009.03497.x. [PubMed: 19496921] [CrossRef]
63.
Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U, SPOG 6. Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial. Thromb Haemost 2008;100:1089–98. [PubMed: 19132235]
64.
Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S, et al. Self management of oral anticoagulation: randomised trial. BMJ 2005;331:1057. 10.1136/bmj.38618.580903.AE. [PMC free article: PMC1283185] [PubMed: 16216821] [CrossRef]
65.
Sunderji R, Gin K, Shalansky K, Carter C, Chambers K, Davies C, et al. A randomized trial of patient self-managed versus physician-managed oral anticoagulation. Can J Cardiol 2004;20:1117–23. [PubMed: 15457308]
66.
Christensen TD. Self-management of oral anticoagulation therapy – methodological and clinical aspects. Dan Med Bull 2011;58:B4284. [PubMed: 21535992]
67.
Fitzmaurice DA, Murray ET, Gee KM, Allan TF, Hobbs FD. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. J Clin Pathol 2002;55:845–9. 10.1136/jcp.55.11.845. [PMC free article: PMC1769803] [PubMed: 12401823] [CrossRef]
68.
Gadisseur AP, Breukink-Engbers WG, Meer FJ, Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med 2003;163:2639–46. 10.1001/archinte.163.21.2639. [PubMed: 14638565] [CrossRef]
69.
Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004;126:557–64. 10.1111/j.1365-2141.2004.05074.x. [PubMed: 15287950] [CrossRef]
70.
Körtke H, Minami K, Breymann T, Seifert D, Baraktaris A, Wagner O, et al. INR self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial). Z Kardiol 2001;90(Suppl. 6):VI/118–24. 10.1007/s003920170019. [PubMed: 24445799] [CrossRef]
71.
Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010;363:1608–20. 10.1056/NEJMoa1002617. [PubMed: 20961244] [CrossRef]
72.
Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999;281:145–50. 10.1001/jama.281.2.145. [PubMed: 9917117] [CrossRef]
73.
Sidhu P, O’Kane HO. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. Ann Thorac Surg 2001;72:1523–7. 10.1016/S0003-4975(01)03049-1. [PubMed: 11722037] [CrossRef]
74.
Verret L, Couturier J, Rozon A, Saudrais-Janecek S, St-Onge A, Nguyen A, et al. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial. Pharmacotherapy 2012;32:871–9. 10.1002/j.1875-9114.2012.01116. [PubMed: 23033226] [CrossRef]
75.
Christensen TD, Maegaard M, Sorensen HT, Hjortdal VE, Hasenkam JM. Self-management versus conventional management of oral anticoagulant therapy: a randomized, controlled trial. Eur J Intern Med 2006;17:260–6. 10.1016/j.ejim.2005.11.021. [PubMed: 16762775] [CrossRef]
76.
Cromheecke ME, Levi M, Colly LP, Mol BJ, Prins MH, Hutten BA, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000;356:97–102. 10.1016/S0140-6736(00)02470-3. [PubMed: 10963245] [CrossRef]
77.
Azarnoush K, Camilleri L, Aublet-Cuvelier B, Geoffroy E, Dauphin C, Dubray C, et al. Results of the first randomised French study evaluating self-testing of the International Normalized Ratio. J Heart Valve Dis 2011;20:518–25. [PubMed: 22066355]
78.
Eitz T, Schenk S, Fritzsche D, Bairaktaris A, Wagner O, Koertke H, et al. International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement. Ann Thorac Surg 2008;85:949–54. 10.1016/j.athoracsur.2007.08.071. [PubMed: 18291177] [CrossRef]
79.
Soliman Hamad MA, van Eekelen E, van Agt T, van Straten AH. Self-management program improves anticoagulation control and quality of life: a prospective randomized study. Eur J Cardiothorac Surg 2009;35:265–9. 10.1016/j.ejcts.2008.10.020. [PubMed: 19041254] [CrossRef]
80.
Gadisseur AP, Kaptein AA, Breukink-Engbers WG, Meer FJ, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thrombo Haemostas 2004;2:584–91. 10.1111/j.1538-7836.2004.00659.x. [PubMed: 15102012] [CrossRef]
81.
Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial. Thromb Haemost 2007;97:408–16. [PubMed: 17334508]
82.
Taborski U, Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin Thromb Hemost 1999;25:103–7. 10.1055/s-2007-996432. [PubMed: 10327229] [CrossRef]
83.
Lafata JE, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000;15:31–7. 10.1046/j.1525-1497.2000.01239.x. [PMC free article: PMC1495325] [PubMed: 10632831] [CrossRef]
84.
Muller E, Bergemann R, GELIA Study Group. Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7). Eur Heart J Suppl 2001;3(Suppl. Q):Q65–9. 10.1016/S1520-765X(01)90046-X. [CrossRef]
85.
Sola-Morales O. Portable Coagulometers: Revision of the Scientific Evidence and Economic Assessment of Their Use in Self-Control of Oral Anticoagulant Treatment. Barcelona: Catalan Agency for Health Technology Assessment and Research (CAHTA); 2003.
86.
Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ 2006;174:1847–52. 10.1503/cmaj.051104. [PMC free article: PMC1475919] [PubMed: 16785459] [CrossRef]
87.
Jowett S, Bryan S, Murray E, McCahon D, Raftery J, Hobbs FD, et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol 2006;134:632–9. 10.1111/j.1365-2141.2006.06243.x. [PubMed: 16938120] [CrossRef]
88.
Medical Advisory Secretariat Ministry of Health and Long-Term Care. Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy. Ontario Health Asssessment Series 9 (12). Toronto, ON: Medical Advisory Secretariat Ministry of Health and Long-Term Care; 2009. URL: www​.health.gov.on.ca​/english/providers/program​/mas/tech/reviews​/pdf/rev_poc_20090928.pdf (accessed October 2013). [PMC free article: PMC3377545] [PubMed: 23074516]
89.
Horstkotte D, Bergemann R, Althaus U, Babin-Ebell J, Chares M, Dahm M, et al. German experience with low intensity anticoagulation (GELIA): protocol of a multi-centre randomzsed, prospective study with the St. Jude Medical valve. J Heart Valve Dis 1993;2:411–19. [PubMed: 8269143]
90.
Visnansky M, Mesaros S. Patient self-testing of oral anticoagulation therapy by CoaguChek® XS system. Rapid health technology assessment in Slovak health care environment. Value Health 2011;14:A257–8. 10.1016/j.jval.2011.08.146. [CrossRef]
91.
Schmidt LJ, Habacher W, Koenig C, Beck P. PCV44 Cost-utility associated with different monitoring strategies among patients receiving long-term oral anticoagulation therapy in Austria. Value Health 2011;14:A372. 10.1016/j.jval.2011.08.765. [CrossRef]
92.
National Insititute for Health and Care Excellence. Rivaroxaban for the Prevention of Stroke and Systemic Embolism in People with Atrial Fibrillation. Technology appraisal TA256. London: National Insititute for Health and Care Excellence; 2012. URL: http://guidance​.nice.org.uk/TA256 (accessed October 2013).
93.
National Insititute for Health and Care Excellence. Dabigatran Etexilate for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation. Technology appraisal TA249. London: National Insititute for Health and Care Excellence; 2012. URL: http://guidance​.nice.org.uk/TA249 (accessed October 2013).
94.
Department of Health. NHS Reference Costs 2011–12. London: Department of Health; 2012. URL: www​.gov.uk/government​/publications/nhs-reference-costs-financial-year-2011-to-2012 (accessed October 2013).
95.
Curtis L. Unit Costs of Health and Social Care 2012. Canterbury: Personal Social Services Research Unit; 2012. URL: www​.pssru.ac.uk/project-pages​/unit-costs/2012/ (accessed October 2013).
96.
Bayer PLC. Single Technology Appraisal (STA) of Rivaroxaban (Xarelto®). London: National Institute for Health and Care Excellence; 2011. URL: www​.nice.org.uk/guidance​/ta256/documents​/atrial-fibrillation-stroke-prevention-rivaroxaban-bayer4 (accessed October 2013).
97.
Edwards S, Hamilton V, Nherera L, Trevor N, Barton S. Rivaroxaban for the Prevention of Stroke and Systemic Embolism in People with Atrial Fibrillation. National Insititute for Health and Care Excellence; 2011. URL: www​.nice.org.uk/guidance​/ta256/documents​/atrial-fibrillation-stroke-prevention-rivaroxaban-evidence-review-group-report3 (accessed October 2013).
98.
ROCKET AF Study Investigators. Rivaroxaban-Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340–7. 10.1016/j.ahj.2009.11.025. [PubMed: 20211293] [CrossRef]
99.
Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975–83. 10.1016/S0140-6736(10)61194-4. [PubMed: 20801496] [CrossRef]
100.
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013;127:2166–76. 10.1161/CIRCULATIONAHA.112.142158. [PubMed: 23640971] [CrossRef]
101.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51. 10.1056/NEJMoa0905561. [PubMed: 19717844] [CrossRef]
102.
Lee S, Monz BU, Clemens A, Brueckmann M, Lip GYH. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open 2012;2:e001768. 10.1136/bmjopen-2012-001768. [PMC free article: PMC3533028] [PubMed: 23242482] [CrossRef]
103.
Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106:968–77. 10.1160/TH11-05-0353. [PubMed: 21901239] [CrossRef]
104.
Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019–26. 10.1056/NEJMoa022913. [PubMed: 12968085] [CrossRef]
105.
Berhringer Ingelheim. Atrial Fibrillation – Dabigatran Etexilate: Boehringer Ingelheim Submission. London: National Insititute for Health and Care Excellence; 2011. URL: www​.nice.org.uk/guidance​/ta249/documents​/atrial-fibrillation-dabigatran-etexilate-boehringer-ingelheim2 (accessed October 2013).
106.
Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049–56. 10.1001/jama.290.8.1049. [PubMed: 12941677] [CrossRef]
107.
Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9(40). 10.3310/hta9400. [PubMed: 16202350] [CrossRef]
108.
Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379:322–34. 10.1016/S0140-6736(11)61294-4. [PubMed: 22137798] [CrossRef]
109.
Ruel M, Masters RG, Rubens FD, Bedard PJ, Pipe AL, Goldstein WG, et al. Late incidence and determinants of stroke after aortic and mitral valve replacement. Ann Thorac Surg 2004;78:77–83. 10.1016/j.athoracsur.2003.12.058. [PubMed: 15223407] [CrossRef]
110.
Ascione R, Culliford L, Rogers CA, Wild J, Narajan P, Angelini GD. Mechanical heart valves in septuagenarians. J Card Surg 2008;23:8–16. 10.1111/j.1540-8191.2007.00504.x. [PubMed: 18290880] [CrossRef]
111.
Sundberg G, Bagust A, Terent A. A model for costs of stroke services. Health Policy 2003;63:81–94. 10.1016/S0168-8510(02)00055-6. [PubMed: 12468120] [CrossRef]
112.
Bronnum-Hansen H, Davidsen M, Thorvaldsen P, Danish MONICA Study Group. Long-term survival and causes of death after stroke. Stroke 2001;32:2131–6. 10.1161/hs0901.094253. [PubMed: 11546907] [CrossRef]
113.
Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007;28:2346–53. 10.1093/eurheartj/ehm308. [PubMed: 17670754] [CrossRef]
114.
Kvidal P, Bergstrom R, Horte LG, Stahle E. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol 2000;35:747–56. 10.1016/S0735-1097(99)00584-7. [PubMed: 10716479] [CrossRef]
115.
Slot KB, Berge E, Dorman P, Lewis S, Dennis M, Sandercock P, et al. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 2008;336:376–9. 10.1136/bmj.39456.688333.BE. [PMC free article: PMC2244762] [PubMed: 18230644] [CrossRef]
116.
Office for National Statistics. Deaths Registered in England and Wales, 2011. London: Office for National Statistics; 2012. URL: www​.ons.gov.uk/ons/rel​/vsob1/mortality-statistics--deaths-registered-in-england-and-wales--series-dr-​/2011/stb-deaths-registered-in-england-and-wales-in-2011-by-cause.html (accessed October 2013).
117.
Office for National Statistics. Interim Life Tables, England and Wales, 2009–2011. London: Office for National Statistics; 2013. URL: www​.ons.gov.uk/ons/rel​/lifetables/interim-life-tables​/2009-2011/stb-2009-2011​.html (accessed October 2013).
118.
Spackman E, Burch J, Faria R, Corbacho B, Fox D, Woolacott N. Dabigatran Etexilate for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation: Evidence Review Group Report. London: National Insititute for Health and Care Excellence; 2011. URL: www​.nice.org.uk/guidance​/ta249/documents​/atrial-fibrillation-dabigatran-etexilate-evidence-review-group-report2 (accessed October 2013).
119.
National Institute for Health and Care Excellence. TA249 Atrial Fibrillation – Dabigatran Etexilate: Costing Template. London: National Institute for Health and Care Excellence; 2012. URL: www​.nice.org.uk/guidance​/ta249/resources​/ta249-atrial-fibrillation-dabigatran-etexilate-costing-template2 (accessed October 2013).
120.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University Press; 2005.
121.
Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472–7. 10.1136/hrt.2004.042465. [PMC free article: PMC1768813] [PubMed: 15772203] [CrossRef]
122.
NHS Purchasing and Supply Agency. Point of Care Coagulometers for Monitoring Oral Anticoagulation: Buyers’ Guide. NHS Purchasing and Supply Agency Centre for Evidence-based Purchasing; 2008. URL: http://nhscep​.useconnect​.co.uk/ShowDocument​.ashx?id=58&i=true (accessed October 2013).
123.
Murray E, Fitzmaurice D, McCahon D, Fuller C, Sandhur H. Training for patients in a randomised controlled trial of self management of warfarin treatment. BMJ 2004;328:437–8. 10.1136/bmj.328.7437.437. [PMC free article: PMC344261] [PubMed: 14976099] [CrossRef]
124.
Saka O, McGuire A, Wolfe C. Cost of stroke in the United Kingdom. Age Ageing 2009;38:27–32. 10.1093/ageing/afn281. [PubMed: 19141506] [CrossRef]
125.
Wardlaw JM, Chappell FM, Stevenson M, De NE, Thomas S, Gillard J, et al. Accurate, practical and cost-effective assessment of carotid stenosis in the UK. Health Technol Assess 2006;10(30). 10.3310/hta10300. [PubMed: 16904049] [CrossRef]
126.
National Insititute for Health and Care Excellence. Venous Thromboembolism – Reducing the Risk. Clinical guideline 92. London: National Insititute for Health and Care Excellence; 2010. URL: http://guidance​.nice​.org.uk/CG92/NICEGuidance/pdf/English (accessed October 2013).
127.
Hallan S, Asberg A, Indredavik B, Wideroe TE. Quality of life after cerebrovascular stroke: a systematic study of patients’ preferences for different functional outcomes. J Intern Med 1999;246:309–16. 10.1046/j.1365-2796.1999.00531.x. [PubMed: 10475999] [CrossRef]
128.
Dorman P, Dennis M, Sandercock P. Are the modified ‘simple questions’ a valid and reliable measure of health related quality of life after stroke? United Kingdom Collaborators in the International Stroke Trial. J Neurol Neurosurg Psychiatry 2000;69:487–93. 10.1136/jnnp.69.4.487. [PMC free article: PMC1737115] [PubMed: 10990509] [CrossRef]
129.
International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569–81. 10.1016/S0140-6736(97)04011-7. [PubMed: 9174558] [CrossRef]
130.
Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. University of York: Centre for Health Economics; 1999. URL: www​.york.ac.uk/media​/che/documents/papers​/discussionpapers/CHE​%20Discussion%20Paper%20172.pdf (accessed October 2013).
131.
Robinson A, Thomson R, Parkin D, Sudlow M, Eccles M. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy 2001;6:92–8. 10.1258/1355819011927288. [PubMed: 11357250] [CrossRef]
132.
Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost-effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;24:1021–33. 10.2165/00019053-200624100-00009. [PubMed: 17002484] [CrossRef]
133.
Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
134.
Marini C, Totaro R, Carolei A. Long-term prognosis of cerebral ischemia in young adults. National Research Council Study Group on stroke in the young. Stroke 1999;30:2320–5. 10.1161/01.STR.30.11.2320. [PubMed: 10548665] [CrossRef]
135.
Wells PS, Brown A, Jaffey J, McGahan L, Poon MC, Cimon K. Safety and effectiveness of point-of-care monitoring devices in patients on oral anticoagulant therapy: a meta-analysis. Open Medicine 2007;1:E131–46. [PMC free article: PMC3113217] [PubMed: 21673942]
136.
Bloomfield HE, Krause A, Greer N, Taylor BC, MacDonald R, Rutks I, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011;154:472–82. 10.7326/0003-4819-154-7-201104050-00005. [PubMed: 21464349] [CrossRef]
137.
Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006;367:404–11. 10.1016/S0140-6736(06)68139-7. [PubMed: 16458764] [CrossRef]
138.
Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol 2007;118:54–61. 10.1016/j.ijcard.2006.06.018. [PubMed: 16891008] [CrossRef]
139.
van WC, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155–66. 10.1378/chest.129.5.1155. [PubMed: 16685005] [CrossRef]
140.
Dauphin C, Legault B, Jaffeux P, Motreff P, Azarnoush K, Joly H et al. Comparison of INR stability between self-monitoring and standard laboratory method: preliminary results of a prospective study in 67 mechanical heart valve patients. Arch Cardiovasc Dis 2008;101:753–61. 10.1016/j.acvd.2008.10.007. [PubMed: 19059570] [CrossRef]
141.
Bauman ME, Conroy S, Massicotte MP. Point-of-care INR measurement in children requiring warfarin: what has been evaluated and future directions. Pediatr Health 2008;2:651–9. 10.2217/17455111.2.5.651. [CrossRef]
142.
Christensen TD, Maegaard M, Sorensen HT, Hjortdal VE, Hasenkam JM. Self- versus conventional management of oral anticoagulant therapy: effects on INR variability and coumarin dose in a randomized controlled trial. Am J Cardiovasc Drug 2007;7:191–7. 10.2165/00129784-200707030-00005. [PubMed: 17610346] [CrossRef]
143.
Koertke H, Zittermann A, Mommertz S, El AM, Litmathe J, Koerfer R. The bad oeynhausen concept of INR self-management. J Thromb Thrombolysis 2005;19:25–31. 10.1007/s11239-005-0937-1. [PubMed: 15976964] [CrossRef]
144.
Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med 2000;160:2343–8. 10.1001/archinte.160.15.2343. [PubMed: 10927732] [CrossRef]
145.
McCahon D, Fitzmaurice DA, Murray ET, Fuller CJ, Hobbs RF, Allan TF, et al. SMART: Self-Management of Anticoagulation, a Randomised Trial [ISRCTN19313375]. BMC Fam Pract 2003;4:11. 10.1186/1471-2296-4-11. [PMC free article: PMC240084] [PubMed: 13678426] [CrossRef]
146.
Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5(Suppl. 1):19–24. 10.1023/A:1013228718768. [PubMed: 10767128] [CrossRef]
147.
Koertke H, Minami K, Bairaktaris A, Wagner O, Koerfer R. INR self-management following mechanical heart valve replacement. J Thromb Thrombolysis 2000;9(Suppl. 1):S41–5. 10.1023/A:1018712520472. [PubMed: 10859584] [CrossRef]
148.
Koertke H, Zittermann A, Wagner O, Koerfer R. Self-management of oral anticoagulation therapy improves long-term survival in patients with mechanical heart valve replacement. Ann Thorac Surg 2007;83:24–9. 10.1016/j.athoracsur.2006.08.036. [PubMed: 17184625] [CrossRef]
149.
Körtke H, Körfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 2001;72:44–8. 10.1016/S0003-4975(01)02656-X. [PubMed: 11465228] [CrossRef]
150.
Matchar DB, Jacobson AK, Edson RG, Lavori PW, Ansell JE, Ezekowitz MD, et al. The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA cooperative study #481 – The Home INR Study (THINRS). J Thromb Thrombolysis 2005;19:163–72. 10.1007/s11239-005-1452-0. [PubMed: 16082603] [CrossRef]
151.
Matchar DB, Dolor R, Jacobson A, Love S, Edson R, Uyeda L. More frequent self-testing of prothrombin time results in improved time in target range. Circulation 2012;126:A10606.
152.
Ryan F, O’Shea S, Byrne S. The ‘carry-over’ effects of patient self-testing: positive effects on usual care management by an anticoagulation management service. Thromb Res 2010;126:e345–8. 10.1016/j.thromres.2010.08.001. [PubMed: 20828796] [CrossRef]
153.
Sawicki PT, Glaser B, Kleespies C, Stubbe J, Schmitz N, Kaiser T, et al. Long-term results of patients’ self-management of oral anticoagulation. J Clin Basic Cardiol 2003;6:59–62.
154.
Sunderji R, Campbell L, Shalansky K, Fung A, Carter C, Gin K. Outpatient self-management of warfarin therapy: a pilot study. Pharmacotherapy 1999;19:787–93. 10.1592/phco.19.9.787.31546. [PubMed: 10391426] [CrossRef]
155.
Voller H, Glatz J, Taborski U, Bernardo A, Dovifat C, Burkard G, et al. Background and evaluation plan of a study on self-management of anticoagulation in patients with non-valvular atrial fibrillation (SMAAF Study). Z Kardiol 2000;89:284–8. [PubMed: 10868001]
Copyright © Queen’s Printer and Controller of HMSO 2015. This work was produced by Sharma et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK304009
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (3.8M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...